SINGAPORE , March 17, 2025 /PRNewswire/ -- HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTTM – now available in the United States . This marks a significant milestone for HistoIndex as the company enters clinical care for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). "I am excited to see how our core expertise in clinical trial assessments is now transcending into the realm of precise and personalized patient care ," said Dr.
Gideon Ho , Chief Executive Officer of HistoIndex." With FibroSIGHT, we aim to empower clinicians with a more definitive and accurate assessment of liver fibrosis." MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left untreated, leads to fibrosis and, ultimately, cirrhosis.
After decades of research and therapeutic development, the field reached a pivotal moment in 2024 with the approval of Rezdiffra ® - the first drug for the treatment of MASH with moderate to advanced fibrosis [1,2*] . As treatment options expand, accurate fibrosis assessment becomes even more critical in guiding clinical decisions and optimizing patient outcomes. HistoIndex has been playing a key role in the development of MASH treatments and is now leading the way in this next phase of patient care with FibroSIGHT.
FibroSIGHT seamlessly integrates int.